VectorXcellerator: OXB has selected the first programmes to move forward through VectorXcellerator, supporting earlier collaboration in advanced therapies.

OXB launches fast-track offering for AAV and lentiviral vector platforms, accelerating viral vector development and manufacture.

Home – News

OXB to present at Jefferies Healthcare Conference

November 9, 2026 | News

OXB to present at the Jefferies Global Healthcare Conference in London

Oxford, UK – 9 November 2026: OXB (LSE: OXB), a global quality and innovation-led cell and gene therapy CDMO, today announces that Dr. Frank Mathias, Chief Executive Officer, will present at the Jefferies Global Healthcare Conference in London on 18 November 2026. Dr. Lucy Crabtree, Chief Financial Officer, will also be participating in the conference.

The presentation will be made available in the Investors section of OXB’s website at www.oxb.com.

For details of this and other upcoming events, please refer to the Company’s investor calendar at https://oxb.com/investor-events/.  

-Ends-

Enquiries:

OXB:

T: +44 (0) 1865 509 737 / E: ir@oxb.com

Sophia Bolhassan, Head of Investor Relations

ICR Healthcare:

T: +44 (0)20 3709 5700 / E: oxb@icrhealthcare.com

Mary-Jane Elliott / Sarah Elton-Farr / Phillip Marriage

About OXB

OXB (LSE: OXB) is a global quality and innovation-led contract development and manufacturing organisation (CDMO) in cell and gene therapy with a mission to enable its clients to deliver life changing therapies to patients around the world.

One of the pioneers in cell and gene therapy, OXB has over 30 years of experience in viral vectors, the driving force behind the majority of cell and gene therapies. OXB collaborates with some of the world’s most innovative pharmaceutical and biotechnology companies, providing development and manufacturing expertise for lentiviral, AAV, adenoviral, MVA and other viral vectors. Building on its viral vector leadership, OXB also supports the development of emerging in vivo therapies through its expertise in vector engineering, manufacturing platforms, and novel envelope technologies. OXB’s world-class capabilities range from early-stage development to commercialisation. These capabilities are supported by robust quality systems, analytical methods and depth of regulatory expertise.

OXB offers a vast number of technologies for viral vector manufacturing, including a 4th generation lentiviral vector system (the TetraVecta™ system), a dual-plasmid system for AAV production, suspension and perfusion process using process enhancers and stable producer and packaging cell lines.

OXB, a FTSE 250 and FTSE4Good constituent, is headquartered in Oxford, UK. It has development and manufacturing facilities across Oxfordshire, UK, Lyon and Strasbourg, France, Bedford MA and Durham NC, US. Learn more at www.oxb.com and follow us on LinkedIn and YouTube.